Finance and markets: business, quotes, gold, energy and releases.
OncoTherapy Science Inc. reported a net loss of ¥574 million for the six months ended September 30, 2026, compared with a ¥555 million loss in the same period a year earlier. Revenue fell to ¥335 million from ¥431 million.
The Japanese company recorded an operating loss of ¥568 million, against ¥475 million in the prior-year period. Its pretax loss widened to ¥572 million from ¥493 million.
Loss per share narrowed to ¥1.42 from ¥1.89. The results are based on Japanese accounting standards.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!